Regulation of immune function in patients with sepsis by electroacupuncture and its correlation analysis with clinical outcome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076171

Enrollment

Unknown

Registered

2023-09-26

Start date

2023-10-01

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Electroacupuncture group:Electroacupuncture was added to the treatment of the control group. Acupoint prescription includes the main points: bilateral Zusanli, Hegu, Tianshu, and Geshu

supporting points: favoring the toxic heat blazing plus the Dazhui and Quchi, favoring the stasis of blood stagnation plus the Xuehai, favoring the acute deficiency evidence plus Guanyuan and Qihai, f

Control group:Therapies such as infection control, hemodynamic management (fluid management, vasoactive agents, positive inotropic agents, monitoring of venous access and fluid balance), and mechanica

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meets the above diagnostic criteria for sepsis; (2) Age between 18-80 years; (3) Patients or proxies were free of psychiatric disorders and voluntarily signed an informed consent form before randomization.

Exclusion criteria

Exclusion criteria: (1) Participation as a subject in other clinical trials in the last three months; (2) Sepsis diagnosis for more than 48 hours; (3) Pregnant and lactating women; (4) Patients with immunodeficiency class disorders or who are using immunosuppressive or immunoenhancing agents; (5) History of malignant tumors; (6) Death expected within 48 hours, or SOFA = 15 points, or APACHE II = 30 points; (7) Contraindications to acupuncture treatment, such as skin breakdown, infection, and severe coagulation disorders.

Design outcomes

Primary

Measure	Time frame
mHLA-DR;28-day all-cause mortality rate;Sequential Organ Failure Assessment (SOFA) score;	—

Secondary

Measure	Time frame
Lymphocyte counts;T-lymphocyte count;CD3+;CD4+;CD8+;CD4+/CD8+;B-lymphocyte count;Regulatory cells (Treg) ratios;Tumor Necrosis Factor-a (TNF-a);Blood Lactate (Lac) Levels;Duration of mechanical ventilation;Acute Physiology and Chronic Health Evaluation-II (APACHE-II) Score;Chinese Medicine Symptom Score;Chinese Medicine Symptoms' Healing Effects;Duration of ICU stay;Length of hospitalization;	—

Countries

China

Contacts

Public ContactLei Ming

Shanghai Seventh People's Hospital

leiming6891@163.com+86 189 3083 7828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026